Market Overview

Cowen Suggests Truth to Allergan Rumors

Related AGN
Benzinga's M&A Chatter for Wednesday July 9, 2014
Novo Nordisk Gets FDA Nod for NovoSeven RT - Analyst Blog
Allergan Rebuffs Valeant's Tender Offer (Fox Business)

Traders continue to build up shares of Allergan Inc. (NYSE: AGN) as account analyst suggests truth to yesterday's rumor.

Cowen analyst Ken Cacciatore cited legal consultants in his note while reporting that the Allergan patent may be issued as early as 4-5 weeks. Cacciatore noted that the patent is being added to the Food and Drug Administration's Orange Book, regardless of the strength of claims. Analysts could confidently model that Allergan would be protected for 30-40 months if no generic applicant is found.

Cowen commented that adding restasis to the model would add at least $0.50 and $1.00 to the adjusted EPS estimate in 2014 and 2015, respectively. The average adjusted EPS estimate is reported to be $5.46 in 2014 according to Bloomberg and $5.96 in 2015.

Shares of Allergan gained 2.6% Thursday and have traded as high as 5.89% on Friday.

Posted-In: Cowen Ken CacciatoreAnalyst Color News Rumors Analyst Ratings

 

Most Popular

Related Articles (AGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free

Benzinga Professional